Mammary Cell News Volume 8.44 | Nov 10 2016

TOP STORY

MMTV-Cre;Ccn6 Knockout Mice Develop Tumors Recapitulating Human Metaplastic Breast Carcinomas

Researchers showed that CCN6, a secreted matricellular protein of the CCN family, is significantly downregulated in clinical samples of human spindle cell metaplastic breast carcinoma. [Oncogene] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Decreased Expression of MicroRNA-17 and MicroRNA-20b Promotes Breast Cancer Resistance to Taxol Therapy by Upregulation of NCOA3

Scientists investigated whether nuclear receptor coactivator 3 (NCOA3) expression was regulated by miRNAs in breast cancer. [Cell Death Dis] Full Article

Fucose-Containing Fraction of Ling-Zhi Enhances Lipid Rafts-Dependent Ubiquitination of TGFβ Receptor Degradation and Attenuates Breast Cancer Tumorigenesis

The authors investigated the molecular mechanism associated with the anti-metastatic activity of fucose-containing fraction of Ling-Zhi in breast cancer. [Sci Rep] Full Article

The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells

Scientists identified the cell line-independent effects of poly (ADP-ribose) polymerase inhibition on breast cancer cell metabolism and compared these effects with the metabolic responses elicited by radiation. [Sci Rep] Full Article

EGF Induces Epithelial-Mesenchymal Transition through Phospho-Smad2/3-Snail Signaling Pathway in Breast Cancer Cells

Investigators determined the mechanism of epidermal growth factor (EGF)-induced epithelial-mesenchymal transition through activating Smad2/3 in MCF-7 and MDA-MB-231 breast cancer cells. [Oncotarget] Full Article

ERN1 and ALPK1 Inhibit Differentiation of Bi-Potential Tumor-Initiating Cells in Human Breast Cancer

Researchers evaluated the impact of knocking down expression of 420 kinases in bi-lineage triple-negative breast cancer cells that express characteristics of both myoepithelial and luminal cells. [Oncotarget] Abstract

New Orally Active DNA Minor Groove Binding Small Molecule CT-1 Acts against Breast Cancer by Targeting Tumor DNA Damage Leading to p53-Dependent Apoptosis

Investigators identified a new orally active small molecule curcumin-triazole conjugate (CT-1) with significant anti-breast cancer activity in vitro and in vivo. [Mol Carcinog] Abstract

Terpolymer Micelles for the Delivery of Arsenic to Breast Cancer Cells: The Effect of Chain Sequence on Polymeric Micellar Characteristics and Cancer Cell Uptake

Scientists evaluated three block sequence isomers of PEO/PCL/PCCL terpolymers with regards to micelle stability, surface charge, arsenic loading, release, and cellular uptake in breast cancer cells. [Mol Pharm] Abstract | Graphical Abstract

CLINICAL RESEARCH

GLUL Promotes Cell Proliferation in Breast Cancer

Researchers investigated the expression of glutamate-ammonia ligase in breast cancer patients. [J Cell Biochem] Abstract

Epithelial Plasticity during Human Breast Morphogenesis and Cancer Progression

The authors discuss the cellular and molecular mechanisms of breast morphogenesis and epithelial to mesenchymal transition and its reversed process mesenchymal to epithelial transition and how these processes can be recapitulated in stromal-rich three-dimensional cell culture assays. [J Mammary Gland Biol Neoplasia] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Glenmark Pharmaceuticals’ Experimental GBR 1302-BEAT™ Demonstrates Potent Anti-Tumor Activity in Preclinical Data

Glenmark Pharmaceuticals announced results of an in vitro study that showed potential for a large therapeutic window for GBR 1302 in destroying HER2⁺ cancer cells compared with normal cells. [Press release from Glenmark Pharmaceuticals Inc. discussing research presented at the 4^th European Society of Medical Oncology (ESMO) Symposium on Immuno-Oncology, Lausanne] Press Release

IBRANCE^® Receives Approval in European Union for the Treatment of Women with HR⁺/HER2^– Metastatic Breast Cancer

Pfizer Inc. announced that the European Commission has approved IBRANCE^® for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR⁺/HER2^–) locally advanced or metastatic breast cancer. [Pfizer Inc.] Press Release

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan N.V. and Biocon Ltd. announced submission of Mylan’s biologics license application for MYL-1401O, a proposed biosimilar trastuzumab, to the U.S. Food and Drug Administration through the 351(K) pathway. This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. [Mylan N.V.] Press Release

NIH to Double Funding for Chronic Fatigue Syndrome, but Patient Distrust Remains

NIH spending for research on the poorly understood disease should rise to roughly $15 million in 2017, doubling the estimated $7.6 million handed out in 2016. The biomedical agency will solicit CFS proposals from outside scientists to establish several collaborative centers for basic and clinical research, and another center to manage their data on the illness. The calls for applications, which will come with dedicated funds from the planned budget increase, are the first of their kind for CFS from the United States’ major medical research funder since 2005. [Science Insider] Editorial

Donald Trump’s US Election Win Stuns Scientists

Republican businessman and reality-television star Donald Trump will be the United States’ next president. Although science played only a bit part in this year’s dramatic, hard-fought campaign, many researchers expressed fear and disbelief as Trump defeated former secretary of state Hillary Clinton. [Nature News] Press Release

The Quiet Rise of the NIH’s Hot New Metric

Biomedical funders worldwide are adopting the US agency’s free Relative Citation Ratio to analyze grant outcomes. [Nature News] Press Release

Big Brain Projects Urged to Aid Public Health

Major brain-mapping projects have multiplied in recent years, as neuroscientists develop new technologies to decipher how the brain works. These initiatives focus on understanding the brain, but the World Health Organization wants to ensure that they work to translate their early discoveries and technological advances into tests and treatments for brain disorders. [Nature News] Editorial

NEW Gordon Research Conference: Stem Cells & Cancer
February 12-17, 2017
Barga, Italy

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – Breast Cancer Research (University of New Mexico Comprehensive Cancer Center)

Postdoctoral Researcher – Breast Cancer Epidemiology (Karolinska Institutet)

Postdoctoral Position – Immunology (Inserm)

Postdoctoral Training Fellow (Institute of Cancer Research)

Research Associate – Patient-Derived Organoid Models of Breast Cancer (King’s College London)

Postdoctoral Fellow – BioMarker Research Cancer (Houston Methodist Research Institute)

Postdoctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami)

Postdoctoral Position – Neovascularization and Cancer Biology (The Ohio State University)

Postdoctoral Associate – Functional Genomics and Cancer (The Jackson Laboratory)

Assistant Professor – Physiology and Biophysics (University of Illinois at Chicago)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.